PNS 2024 Annual Meeting Highlights
2023 Guideline Update on Diagnosis and Treatment of Guillain–Barré Syndrome
A task force from the European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) used the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) methodology to develop an evidence-based guideline for diagnosing and treating Guillain–Barré syndrome (GBS).
June 25, 2024
Read more
Unmet Needs and Challenges in Diagnosis and Treatment of Multifocal Motor Neuropathy
Multifocal Motor Neuropathy (MMN) is often mistaken for other motor neuron diseases, such as Amyotrophic Lateral Sclerosis (ALS). At the 2024 Peripheral Nerve Society (PNS) annual meeting in Montreal, Canada, Richard Lewis, Professor of Neurology at Cedars-Sinai, Los Angeles, CA, USA, and Katie Beadon, Assistant Clinical Professor at the University of British Columbia, Canada, highlighted the complexities and unmet needs of MMN diagnosis and treatment in an Argenx-sponsored symposium.
June 26, 2024
Read moreRelated Articles
Chronic Activation of Toll-Like Receptor 4 Decreases Peripheral Nerve Integrity
Despite its prevalence and impact on quality of life, understanding the pathogenesis of Diabetic peripheral neuropathy (DPN) and developing targeted interventions has been challenging. Sarah Crowards, a PhD student from Dr Douglas Wright's lab at the University of Kansas Medical Center, presented her research on Toll-like receptor 4 (TLR4) and its involvement in peripheral neuropathy, including diabetic neuropathy, during the Education Day at the 2024 Peripheral Nerve System (PNS) Annual Meeting in Montreal, Canada.
June 25, 2024
Read more
Novel Whole Genome Sequencing Approaches and Lessons for Neuropathies
Technological advancements and cost efficiencies in whole genome sequencing are driving the discovery of repeat expansions associated with inherited neuropathies. Dr. Stephan Zuchner, Professor of Human Genetics and Neurology at the University of Miami Miller School of Medicine, highlighted the importance of long-range human genome sequencing at the 2024 Peripheral Nerve System (PNS) Annual Meeting in Montreal, Canada, noting that approaches like PacBio, Oxford Nanopore, and Optical Genome Mapping are crucial for evaluating neuropathy-associated structural variations. He pointed out the challenges of next-generation sequencing (NGS) technologies: a significant portion of variations fall outside the coding region, and half of our genome is comprised of repeat elements.
June 25, 2024
Read more
Understanding Neuropathic Pain Mechanisms in the Human Dorsal Root Ganglion with Spatial Transcriptomics and Single-Cell RNA Analysis
Cellular heterogeneity in neuropathic pain mechanisms presents a significant challenge, as it involves diverse cell types within the dorsal root ganglion (DRG) of the peripheral nervous system (PNS). This complexity hinders understanding specific cell roles in pain. At the 2024 PNS Annual Meeting, Dr. Theodore Price, Professor of Neuroscience at the University of Texas at Dallas, focused on leveraging next-generation single-cell RNA sequencing technologies to gain a deeper understanding of neuropathic pain mechanisms in the human DRG.
June 25, 2024
Read more
Evolving Understanding of CIDP: Pathophysiology, Rationale for Targeting FcRn, and Results From ADHERE Trial
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) was the focal point of a symposium by three experts at the 2024 Peripheral Nerve System (PNS) Annual Meeting. Thomas Harbo, a neurologist at Aarhus University Hospital, discussed the CIDP Disease Overview and Current Treatment Landscape. Karissa Gable, an associate professor of neurology at Duke University, shared insights on the Potential Role of IgG in the Pathophysiology of CIDP and the Rationale for FcRn Targeting. Jeffery Allen, an associate professor of neurology at the University of Minnesota, presented the results of the ADHERE study in adult patients with CIDP.
June 25, 2024
Read more
What Would be the Ideal Design of a Clinical Trial for CMT1A
Designing an ideal clinical trial for Charcot-Marie-Tooth disease type 1A (CMT1A) presents significant challenges due to the limited understanding of the disease landscape.
June 26, 2024
Read more
New Electrode Technology Offers Hope for Diagnosing Small Fiber Neuropathy
A surface electrode, known as 150IDE, promises to revolutionize the diagnosis of small fiber neuropathy (SFN), a condition difficult to detect with current tests. Sara Massucco, a neurologist from Università degli Studi di Genova, presented her research on SFN diagnosis in a flash presentation at the 2024 Peripheral Nerve Society (PNS) annual meeting in Montreal, Canada.
June 26, 2024
Read more
Advances and Challenges in MMN Treatment: The Role of IVIG and Novel Therapies
Intravenous immunoglobulin (IVIG) remains a cornerstone in treating Multifocal Motor Neuropathy (MMN). However, its use has drawbacks and limitations. 'Most patients with MMN require long-term maintenance therapy with IVig to avoid clinical deterioration,' said Hans Katzberg (an Associate Professor of Neurology) at the University of Toronto in his speech at the 2024 Peripheral Nerve Society (PNS) annual meeting in Montreal, Canada. Despite continuous treatment, a significant proportion of MMN patients still experience disease progression and a gradual loss of muscle strength.
June 26, 2024
Read more
New Insights into the Hippo Pathway: TEAD1 Essential for Myelination and Nerve Repair
The Hippo pathway appears crucial for both the initial myelination of axons and their remyelination following injury, making it a potential target for therapeutic interventions in neuropathies.
June 26, 2024
Read more
© 2024 Wolters Kluwer. All right reserved.